Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVSEF) EBITDA (2016 - 2025)

Historic EBITDA for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $3.6 billion.

  • Novartis Ag's EBITDA rose 243.63% to $3.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $17.6 billion, marking a year-over-year increase of 2131.46%. This contributed to the annual value of $17.6 billion for FY2025, which is 2131.46% up from last year.
  • As of Q4 2025, Novartis Ag's EBITDA stood at $3.6 billion, which was up 243.63% from $4.5 billion recorded in Q3 2025.
  • Over the past 5 years, Novartis Ag's EBITDA peaked at $4.9 billion during Q2 2025, and registered a low of $1.8 billion during Q4 2022.
  • Over the past 5 years, Novartis Ag's median EBITDA value was $3.0 billion (recorded in 2021), while the average stood at $3.1 billion.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 3595.86% in 2022, then surged by 10584.56% in 2024.
  • Quarter analysis of 5 years shows Novartis Ag's EBITDA stood at $2.6 billion in 2021, then crashed by 31.5% to $1.8 billion in 2022, then surged by 47.12% to $2.6 billion in 2023, then soared by 36.72% to $3.5 billion in 2024, then rose by 2.44% to $3.6 billion in 2025.
  • Its EBITDA stands at $3.6 billion for Q4 2025, versus $4.5 billion for Q3 2025 and $4.9 billion for Q2 2025.